Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Haematology

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ejh.12827PMID 27862375
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant

  2016cited by this paper
• Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

  2016cited by this paper
• Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature

  2016cited by this paper
• A nationwide survey of co-occurrence of malignant lymphomas and myelodysplastic syndromes/myeloproliferative neoplasms

  2016cited by this paper
• Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

  2016cited by this paper
• Myelodysplastic syndrome with 5q deletion following IgM monoclonal gammopathy, showing gene mutation MYD88 L265P.

  2015cited by this paper
• SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

  2015cited by this paper
• Genomic heterogeneity in multiple myeloma.

  2015cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014influential reference
• Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases

  2014cited by this paper
• The role of epigenetics in the biology of multiple myeloma

  2014cited by this paper
• Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

  2014cited by this paper
• Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

  2014influential reference
• Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

  2013cited by this paper
• Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide

  2013cited by this paper
• Clinical and biological implications of driver mutations in myelodysplastic syndromes.

  2013cited by this paper
• Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells

  2013cited by this paper
• Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.

  2013cited by this paper
• Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients

  2013cited by this paper
• Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

  2013cited by this paper
• 5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.

  2013cited by this paper
• Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

  2013cited by this paper
• TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

  2013cited by this paper
• New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

  2012cited by this paper
• Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms

  2012cited by this paper
• A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

  2012cited by this paper
• Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• Quality of life and physicians' perception in myelodysplastic syndromes.

  2012cited by this paper
• Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

  2012cited by this paper
• Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone

  2011cited by this paper
• Clinical effect of point mutations in myelodysplastic syndromes.

  2011influential reference
• A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

  2011cited by this paper
• Multiple myeloma.

  2011cited by this paper
• Frequent pathway mutations of splicing machinery in myelodysplasia

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

  2011cited by this paper
• TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

  2011cited by this paper
• Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

  2011cited by this paper
• Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma

  2010cited by this paper
• Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

  2010cited by this paper
• Persistent malignant stem cells in del(5q) myelodysplasia in remission.

  2010cited by this paper
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

  2010cited by this paper
• Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

  2010cited by this paper
• Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

  2010cited by this paper
• Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

  2010cited by this paper
• Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

  2009cited by this paper
• Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

  2009cited by this paper
• Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.

  2009cited by this paper
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

  2009cited by this paper
• Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

  2008cited by this paper
• Clinical and biological significance of RAS mutations in multiple myeloma

  2008cited by this paper
• Genetic aberrations and survival in plasma cell leukemia

  2008cited by this paper
• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

  2007cited by this paper
• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

  2007cited by this paper
• Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q

  2007cited by this paper
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

  2006cited by this paper
• Efficacy of lenalidomide in myelodysplastic syndromes.

  2005cited by this paper
• MDS/AML‐associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q)

  2004cited by this paper
• Clinical and biologic implications of recurrent genomic aberrations in myeloma.

  2003cited by this paper
• Genomic abnormalities in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• Thalidomide Paradoxical Effect on Concomitant Multiple Myeloma and Myelodysplasia

  2002cited by this paper
• Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.

  2001cited by this paper
• International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome

  2001cited by this paper
• Simultaneous occurrence of the 5q- syndrome and multiple myeloma.

  2000cited by this paper
• Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

  1998cited by this paper
• Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes.

  1996cited by this paper
• Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia.

  1996cited by this paper
• TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities.

  1995cited by this paper
• Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.

  1995cited by this paper
• Chronic lymphocytic leukemia coexisting with chronic myelomonocytic leukemia.

  1992cited by this paper
• Immunological abnormalities in myelodysplastic syndromes II. COEXISTENT LYMPHOID OR PLASMA CELL NEOPLASMS: A REPORT OF 20 CASES UNRELATED TO CHEMOTHERAPY

  1986cited by this paper
• Concurrent development of preleukaemic, lymphoproliferative and plasma cell disorders

  1983cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Myelodysplastic Syndrome Accompanied by Monoclonal Gammopathy of Undetermined Significance and Blastic Plasmacytoid Dendritic Cell Neoplasm Treated by Venetocla + Azacitidine.

  2025cites this paper
• Co-occurrence of High-Risk Myelodysplastic Syndrome With a Complex Karyotype/TP53 Mutation and IgG Lambda Monoclonal Gammopathy of Undetermined Significance

  2024cites this paper
• Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

  2024cites this paper
• Coexistence of plasma cell neoplasia and myelodysplastic syndrome with excess blasts: case reports and literature review.

  2021cites this paper
• Successful Treatment of Concurrently Diagnosed Multiple Myeloma and Myelodysplastic Syndrome With Isolated Del(5q) With Lenalidomide, Bortezomib, and Dexamethasone

  2020cites this paper
• Identification of two independent clones underlying the co‐existence of myelodysplastic syndrome with excess of blasts type 2 and isolated 5q‐ and smouldering multiple myeloma

  2020influential citation
• Współistnienie dyskrazji komórek plazmatycznych i zespołu mielodysplastycznego — opisy przypadków i przegląd piśmiennictwa

  2017influential citation
• Etude moléculaire de l'évolution clonalede TP53 des Syndromes Myélodysplasiques avec del(5q) : conséquences sur la résistance au traitement et la progression du cancer

  2017cites this paper